Innova Captab Limited has informed the Exchange about Transcript
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Innova Captab reported its highest ever annual performance for FY '26 with revenue of INR 1,630 crores, up 31% YoY. Q4 revenue stood at INR 448 crores with 42% growth. The CDMO business grew 24% to INR 1,133 crores while Branded Generics surged 51% to INR 497 crores. EBITDA for the year was INR 250.3 crores with 15.4% margin, while PAT reached INR 140.9 crores with 10% growth. The Jammu facility achieved INR 300 crores full-year revenue and is near EBITDA breakeven with Q4 run rate of INR 90 crores. Sharon Bio contributed INR 240 crores in revenue. Exports comprised 31% of total revenue. The company received UK-MHRA approval for its cephalosporin facility and PIC/S certification for Jammu blocks.
Strong execution with 20%+ revenue growth guidance maintained. Management expects EBITDA growth to outperform revenue and PAT growth to outpace EBITDA due to operating leverage from Jammu ramp-up. New Baddi plant expansion planned with INR 150-170 crores capex to drive future growth.